Incyte Corp.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Incyte Corp.
Ownership
Public
Status
Active
Headquarters country
United States
Ticker symbol
INCY
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0000879169

Board of directors

Follow this board

Chief executives

Herve Hoppenot · Special Advisor to the CEO
Dates unknown
William Meury · Chief Executive Officer
Since June 2025

Board connections

11 of this board's directors also sit on 29 other boards.

Network of Incyte Corp.'s board connections ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals... Bicycle Therapeutics plc Bicycle Therapeutics p... Madrigal Pharmaceuticals Inc. Madrigal Pharmaceutica... BeOne Medicines Ltd. BeOne Medicines Ltd. DBV Technologies S.A. DBV Technologies S.A. Denali Therapeutics Inc. Denali Therapeutics In... Immunocore Holdings plc Immunocore Holdings pl... Kiniksa Pharmaceuticals International plc Kiniksa Pharmaceutical... Kodiak Sciences Inc Kodiak Sciences Inc Kymera Therapeutics Inc. Kymera Therapeutics In... Neurogene Inc. Neurogene Inc. Prelude Therapeutics Incorporated Prelude Therapeutics I... Replimune Group Inc. Replimune Group Inc. TScan Therapeutics Inc. TScan Therapeutics Inc... vTv Therapeutics Inc. vTv Therapeutics Inc. Agilent Technologies Inc. Agilent Technologies I... Edmund Harrigan Edmund Harrigan Felix Baker Felix Baker Herve Hoppenot Herve Hoppenot Jacqualyn A. Fouse Jacqualyn A. Fouse Julian Baker Julian Baker Otis W. Brawley Otis W. Brawley Incyte Corp.
Shared director Other board Same sector +13 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$58,337,525
49 sales by 10 insiders
Date Insider Transaction Shares Price Value
Sep 22, 2026 Gardner David H Officer (EVP, Chief Strategy Officer) Shares withheld for tax −920 $126.93 $116,776
Sep 15, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Option exercise +2,957 $61.76 $182,624
Sep 15, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Option exercise +4,551 $61.18 $278,430
Sep 15, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Option exercise +6,477 $64.25 $416,147
Sep 15, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Option exercise +9,233 $71.93 $664,130
Sep 15, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Open-market sale −9,233 $120.50 $1,112,577
Sep 15, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Open-market sale −13,985 $120.49 $1,685,053
Aug 25, 2026 Basi Ramitpal K Officer (EVP, Human Resources) Shares withheld for tax −504 $129.72 $65,379
Aug 19, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Open-market sale −10,801 $125.56 $1,356,174
Aug 12, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Open-market sale −10,803 $120.04 $1,296,792
Aug 5, 2026 CAGNONI PABLO J Officer (President, Global Head of R&D) Open-market sale −10,640 $122.69 $1,305,422
Aug 5, 2026 Mayes Patrick A Officer (EVP & Chief Scientific Officer) Option exercise +2,207 $106.47 $234,979
Aug 5, 2026 Mayes Patrick A Officer (EVP & Chief Scientific Officer) Open-market sale −2,207 $123.99 $273,646
Aug 3, 2026 Mayes Patrick A Officer (EVP & Chief Scientific Officer) Option exercise +6,055 $105.43 $638,379
Aug 3, 2026 Mayes Patrick A Officer (EVP & Chief Scientific Officer) Open-market sale −6,055 $120.43 $729,204

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.